HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.

AbstractOBJECT:
Irinotecan (CPT-11), a topoisomerase I inhibitor, is a cytotoxic agent with activity against malignant gliomas and other tumors. After systemic delivery, CPT-11 is converted to its active metabolite, SN-38, which displays significantly higher cytotoxic potency. However, the achievement of therapeutically effective plasma levels of CPT-11 and SN-38 is seriously complicated by variables that affect drug metabolism in the liver. Thus the capacity of CPT-11 to be converted to the active SN38 intratumorally in gliomas was addressed.
METHODS:
For in vitro studies, 2 glioma cell lines, U87 and U251, were tested to determine the cytotoxic effects of CPT-11 and SN-38 in a dose-dependent manner. In vivo studies were performed by implanting U87 intracranially into athymic/nude mice. For a period of 2 weeks, SN-38, CPT-11, or vehicle was administered intratumorally by means of an osmotic minipump. One series of experiments measured the presence of SN-38 or CPT-11 in the tumor and surrounding brain tissues after 2 weeks' exposure to the drug. In a second series of experiments, after 2 weeks' exposure to the drug, the animals were maintained, in the absence of drug, until death. The survival curves were then calculated.
RESULTS:
The results show that the animals that had CPT-11 delivered intratumorally by the minipump expressed SN-38 in vivo. Furthermore, both CPT-11 and SN-38 accumulated at higher levels in tumor tissues compared with uninvolved brain. Intratumoral delivery of CPT-11 or SN-38 extended the average survival time of tumor-bearing animals from 22 days to 46 and 65 days, respectively.
CONCLUSIONS:
These results demonstrate that intratumorally administered CPT-11 can be effectively converted to SN-38 and this method of drug delivery is effective in extending the survival time of animals bearing malignant gliomas.
AuthorsWeijun Wang, Alex Ghandi, Leonard Liebes, Stan G Louie, Florence M Hofman, Axel H Schönthal, Thomas C Chen
JournalJournal of neurosurgery (J Neurosurg) Vol. 114 Issue 3 Pg. 689-94 (Mar 2011) ISSN: 1933-0693 [Electronic] United States
PMID20415520 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Drug Implants
  • Irinotecan
  • Camptothecin
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (pharmacokinetics)
  • Brain (metabolism)
  • Brain Neoplasms (drug therapy, metabolism)
  • Camptothecin (analogs & derivatives, metabolism, pharmacokinetics)
  • Cell Line, Tumor
  • Cell Survival
  • Chromatography, High Pressure Liquid
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems
  • Drug Implants
  • Glioma (drug therapy, metabolism)
  • Humans
  • Irinotecan
  • Mice
  • Mice, Nude
  • Survival Analysis
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: